Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma
Abstract While CD19-directed CAR T-cell therapy represents a transformative immunotherapy for relapsed/refractory large B-cell lymphoma (r/r LBCL), more than 50% of patients ultimately progress or relapse. Recently, the International Metabolic Prognostic Index (IMPI) – incorporating age, stage, and...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group
2025-08-01
|
| Col·lecció: | Blood Cancer Journal |
| Accés en línia: | https://doi.org/10.1038/s41408-025-01338-1 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
